MannKind Corporation (MNKD): Price and Financial Metrics


MannKind Corporation (MNKD): $5.23

-0.08 (-1.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNKD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNKD POWR Grades

  • MNKD scores best on the Growth dimension, with a Growth rank ahead of 80.4% of US stocks.
  • The strongest trend for MNKD is in Growth, which has been heading up over the past 177 days.
  • MNKD's current lowest rank is in the Stability metric (where it is better than 6.56% of US stocks).

MNKD Stock Summary

  • MANNKIND CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.96% of US listed stocks.
  • MNKD's price/sales ratio is 18.33; that's higher than the P/S ratio of 93.61% of US stocks.
  • MNKD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.28% of US stocks.
  • Stocks that are quantitatively similar to MNKD, based on their financial statements, market capitalization, and price volatility, are AGE, KTOS, TALK, CLS, and APEN.
  • Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to www.mannkindcorp.com.

MNKD Valuation Summary

  • MNKD's price/sales ratio is 16.4; this is 700% higher than that of the median Healthcare stock.
  • MNKD's price/sales ratio has moved NA NA over the prior 225 months.

Below are key valuation metrics over time for MNKD.

Stock Date P/S P/B P/E EV/EBIT
MNKD 2023-01-20 16.4 -5.3 -12.8 -21.4
MNKD 2023-01-19 15.6 -5.0 -12.2 -20.5
MNKD 2023-01-18 15.7 -5.0 -12.3 -20.7
MNKD 2023-01-17 15.8 -5.1 -12.3 -20.7
MNKD 2023-01-13 16.7 -5.3 -13.0 -21.6
MNKD 2023-01-12 17.2 -5.5 -13.4 -22.2

MNKD Growth Metrics

    Its 5 year price growth rate is now at -17.5%.
  • The 2 year revenue growth rate now stands at 13.22%.
  • Its year over year price growth rate is now at -23.63%.
Over the past 67 months, MNKD's revenue has gone down $101,541,000.

The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 76.226 -90.65 -97.514
2022-06-30 65.612 -77.761 -87.508
2022-03-31 69.998 -67.226 -94.008
2021-12-31 75.442 -61.709 -80.926
2021-09-30 81.37 -49.127 -79.276
2021-06-30 74.511 -47.403 -86.105

MNKD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNKD has a Quality Grade of C, ranking ahead of 42.97% of graded US stocks.
  • MNKD's asset turnover comes in at 0.384 -- ranking 124th of 680 Pharmaceutical Products stocks.
  • VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.

The table below shows MNKD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.384 0.611 -0.321
2021-03-31 0.424 0.627 -0.330
2020-12-31 0.673 0.622 -0.564
2020-09-30 0.673 0.595 -0.391
2020-06-30 0.666 0.529 -0.297
2020-03-31 0.705 0.516 -0.324

MNKD Price Target

For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.33 (Strong Buy)

MNKD Stock Price Chart Interactive Chart >

Price chart for MNKD

MNKD Price/Volume Stats

Current price $5.23 52-week high $5.47
Prev. close $5.31 52-week low $2.49
Day low $5.17 Volume 1,876,261
Day high $5.35 Avg. volume 3,484,731
50-day MA $4.82 Dividend yield N/A
200-day MA $3.94 Market Cap 1.38B

MannKind Corporation (MNKD) Company Bio


MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.


MNKD Latest News Stream


Event/Time News Detail
Loading, please wait...

MNKD Latest Social Stream


Loading social stream, please wait...

View Full MNKD Social Stream

Latest MNKD News From Around the Web

Below are the latest news stories about MANNKIND CORP that investors may wish to consider to help them evaluate MNKD as an investment opportunity.

MannKind Corporation to Participate in the Lytham Partners Investor Select Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Steven B. Binder, will participate in the Lytham Partners Investor Select Conference taking place virtually on Tuesday, Ja

Yahoo | January 24, 2023

MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effectsPaper published on clofazimine inhalation suspension demonstrates promising tolerability and toxicokinetics for treating pulmonary NTM infection DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and co

Yahoo | January 23, 2023

3 Biotech Stocks Under $15 Worth a Second Look in 2023

Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.

Yahoo | January 18, 2023

MannKind's (NASDAQ:MNKD) investors will be pleased with their impressive 183% return over the last three years

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Yahoo | January 17, 2023

MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco,

Yahoo | January 5, 2023

Read More 'MNKD' Stories Here

MNKD Price Returns

1-mo 3.16%
3-mo 49.86%
6-mo 51.59%
1-year 54.28%
3-year 235.26%
5-year 87.46%
YTD -0.76%
2022 20.59%
2021 39.62%
2020 142.64%
2019 21.70%
2018 -54.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6822 seconds.